Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $154
Quest Diagnostics Analyst Ratings
Baird Adjusts Price Target on Quest Diagnostics to $154 From $153
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $150
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating
A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $144 to $154
Truist Financial Sticks to Its Hold Rating for Quest Diagnostics (DGX)
Quest Diagnostics' (DGX) Haystack Oncology Forges New MRD Deal
Quest Diagnostics Incorporated's (NYSE:DGX) Intrinsic Value Is Potentially 95% Above Its Share Price
Quest Diagnostics: A Balanced Hold Rating Amidst Modest Growth and Market Volatility
Express News | Quest Diagnostics Inc : Leerink Partners Raises Target Price to $154 From $151
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday?
Quest Sees Businesses Pull Back From Drug Testing -- Market Talk
Leerink Partners Adjusts Quest Diagnostics Price Target to $154 From $151, Maintains Market Perform Rating
Express News | Quest Diagnostics Shares Are Trading Lower. The Company Reported Q2 Financial Results
Quest Diagnostics on Pace for Largest Percent Decrease Since July 2023 -- Data Talk
Express News | Quest Diagnostics Shares Down 2.1% ; Co Reports Q2 Results
Buy Rating Affirmed for Quest Diagnostics Amid Strong Q2 Financials and Upbeat 2024 Guidance
Quest Diagnostics (NYSE:DGX) Has Some Way To Go To Become A Multi-Bagger